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What happened to anti‑malarial markets
after the Affordable Medicines Facility‑malaria
pilot? Trends in ACT availability, price
and market share from five African countries
under continuation of the private sector
co‑payment mechanism
ACTwatch Group1*, Sarah Tougher2, Kara Hanson2† and Catherine Goodman2†

Abstract
Background: The private sector supplies anti-malarial treatment for large proportions of patients in sub-Saharan
Africa. Following the large-scale piloting of the Affordable Medicines Facility-malaria (AMFm) from 2010 to 2011, a
private sector co-payment mechanism (CPM) provided continuation of private sector subsidies for quality-assured
artemisinin combination therapies (QAACT). This article analyses for the first time the extent to which improvements
in private sector QAACT supply and distribution observed during the AMFm were maintained or intensified during
continuation of the CPM through 2015 in Kenya, Madagascar, Nigeria, Tanzania and Uganda using repeat cross-sectional outlet survey data.
Results: QAACT market share in all five countries increased during the AMFm period (p < 0.001). According to the
data from the last ACTwatch survey round, in all study countries except Madagascar, AMFm levels of private sector
QAACT availability were maintained or improved. In 2014/15, private sector QAACT availability was greater than 70%
in Nigeria (84.3%), Kenya (70.5%), Tanzania (83.0%) and Uganda (77.1%), but only 11.2% in Madagascar. QAACT market
share was maintained or improved post-AMFm in Nigeria, Tanzania and Uganda, but statistically significant declines
were observed in Kenya and Madagascar. In 2014/5, QAACT market share was highest in Kenya and Uganda (48.2 and
47.5%, respectively) followed by Tanzania (39.2%), Nigeria (35.0%), and Madagascar (7.0%). Four of the five countries
experienced significant decreases in median QAACT price during the AMFm period. Private sector QAACT prices
were maintained or further reduced in Tanzania, Nigeria and Uganda, but prices increased significantly in Kenya and
Madagascar. SP prices were consistently lower than those of QAACT in the AMFm period, with the exception of Kenya
and Tanzania in 2011, where they were equal. In 2014/5 QAACT remained two to three times more expensive than the
most popular non-artemisinin therapy in all countries except Tanzania.
Conclusions: Results suggest that a private sector co-payment mechanism for QAACT implemented at national
scale for 5 years was associated with positive and sustained improvements in QAACT availability, price and market
share in Nigeria, Tanzania and Uganda, with more mixed results in Kenya, and few improvements in Madagascar. The
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subsidy mechanism as implemented over time across countries was not sufficient on its own to achieve optimal
QAACT uptake. Supporting interventions to address continued availability and distribution of non-artemisinin therapies, and to create demand for QAACT among providers and consumers need to be effectively implemented to realize the full potential of this subsidy mechanism. Furthermore, there is need for comprehensive market assessments to
identify contemporary market barriers to high coverage with both confirmatory testing and appropriate treatment.
Keywords: Artemisinin combination therapy, Private sector, Case management, Global Fund, Malaria treatment

Background
The private sector is key to the provision of malaria treatment in many countries in sub-Saharan Africa, constituting a substantial proportion of the overall market [1], and
tending to reach the poorest segments of many societies
[2]. However, in many cases, sub-Saharan African private
sector anti-malarial markets have been characterized by a
predominance of anti-malarial medicines that are banned
or no longer recommended, including non-artemisinin
therapies and artemisinin monotherapies [1]. Uptake of
the World Health Organization’s recommended first-line
treatment for uncomplicated malaria, artemisinin-based
combination therapy (ACT) [3], has in the past been limited by a lack of consumer access [1, 4], and when available,
high relative costs outside of the public sector [5, 6]. Inadequate access to prompt and effective treatment continues to contribute to malaria deaths in endemic countries
of sub-Saharan Africa; of the 438,000 global deaths from
malaria in 2015, 90% reportedly occurred in the region [7].
In order to increase utilization of the most effective
treatments for malaria, the Affordable Medicines Facilitymalaria (AMFm) was established by the Global Fund to
Fight AIDS, Tuberculosis and Malaria (the Global Fund,
hereafter) in 2010 with the aim of increasing uptake of
quality-assured ACT medicines (QAACT) and decreasing
use of artemisinin monotherapies. The AMFm aimed to
(1) increase affordability, (2) increase availability and (3)
increase use of QAACT, and (4) to crowd out artemisinin
monotherapies. The AMFm consisted of nine pilots in
eight countries (Cambodia, Ghana, Kenya, Madagascar,
Niger, Nigeria, Uganda, and Tanzania mainland and Zanzibar) (although Cambodia was not included in the independent evaluation due to implementation delays). The
AMFm aimed to achieve its four goals through negotiating QAACT price reductions from manufacturers, and
subsidizing their prices through co-payment, administered at the manufacturer level. Supporting interventions
for the subsidy programme included behaviour change
communications (BCC), the training of private sector
vendors, and the introduction of recommended retail
prices for QAACT. All Global Fund subsidised QAACT
packaging carried a green leaf logo which was promoted
in demand creation activities as an indication of quality
and affordable anti-malarial treatment.

An independent evaluation of the AMFm in 2012 demonstrated substantial increases in availability and market
share, and large price decreases for QAACT in six out
of eight pilots. The results of the AMFm evaluation have
been described in detail elsewhere [8–10]. Briefly, the
benchmark of a 20% point increase in QAACT availability was met in five out of the eight pilots. The benchmark
of a 10% point increase in QAACT market share was met
in four pilots, with a further three having weak statistical
evidence. Finally, the benchmark of QAACT prices falling below three times the price of the most popular nonACT anti-malarial in the country was met in five pilots.
When applied to the private sector alone, the independent evaluation’s conclusions regarding the success metrics
still hold. Positive market shifts were found to be largely
due to changes in the private for-profit sectors in pilot
countries [9]; indeed, the subsidy facility was described
as a ‘game changer’ in the private for-profit sectors of all
but two countries by the independent evaluators [8]. A
systematic review of the literature examining the effects
of anti-malarial subsidies likewise found subsidies to be
successful in increasing availability and reducing costs of
ACT. Furthermore, improved availability and affordability tended to be equitable between rural and urban areas,
and across income gradients [11]. The AMFm evaluation
also found this to be the case in several pilots [8]. Following the AMFm period, the Global Fund continued a
QAACT subsidy programme termed the private sector
co-payment mechanism (CPM). The CPM has been in
operation at national scale in six countries since the end
of the AMFm pilot and the subsequent transition period
in 2013. However, there is no published evidence to-date
on the effectiveness of the CPM. This paper addresses
that gap by examining post-pilot evidence in five countries: Nigeria, Kenya, Madagascar, Tanzania and Uganda.
Description of the private sector co‑payment mechanism

Following on the AMFm pilot phase from 2010 to 2011,
the programme of subsidies and price negotiations continued in six countries: Ghana, Kenya, Madagascar,
Nigeria, Tanzania and Uganda. Initial support for the
subsidy provided by AMFm Phase 1 donors (i.e., Bill and
Melinda Gates Foundation, UK Department for International Development [DFID], Government of Canada and
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UNITAID) continued during a transition period, until
implementation of a mechanism funded by the Global
Fund called the CPM for ACT. The grant-funded CPM
may now be included as part of a country’s malaria funding application to the Global Fund.
Figure 1 summarizes quantities of co-paid ACT delivered to the private sector during the AMFm period and
the CPM through 2015 within the five countries included
in this study (all CPM countries except Ghana), and references the population size of each country [12] (Personal
Communication, Global Fund Sourcing Department
2016). Within each country, the peak for delivery of copaid doses occurred after the evaluated pilot period, 2015
in Nigeria, or in 2012 or 2013 for the other four countries.
The CPM operated using the three key elements of the
AMFm: price negotiations with manufacturers, ACT subsidies at ‘factory gate’, and additional supporting interventions. The CPM focuses exclusively on the private for-profit
sector supply of QAACT given that the independent evaluation showed that AMFm had greater impact on the supply of QAACT in the private than the public sector. Prior to
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the AMFm period, the Global Fund was a primary source
of funding for QAACT within the public sector of pilot
countries [9], and this funding support for the public sector continued post-AMFm outside of the CPM. The CPM
therefore complemented Global Fund support to the public
sector by providing a mechanism for improving access to
QAACT in the private sector with the aim of reaching the
large proportion of the population in participating countries seeking fever treatment in this sector.
The extent to which supporting interventions were
implemented within each country post-AMFm varied
greatly. Mass communication campaigns, private provider training, independent monitoring of retail price
and availability, and policy and/or regulatory changes
were implemented at various time points in the five
countries examined here (Fig. 2) (Personal Communication, National Malaria Control Programmes).
The AMFm was characterized by a high degree of centralized management by a dedicated Global Fund Secretariat. In the transition to the CPM, many aspects that
had been centrally managed and controlled under the

Fig. 1 Quantity of co-paid ACT delivered to private sector first-line buyers, 2010–2015
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Q2
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Mass communicaon campaigns to increase public awareness about the co-payment and important
aributes of co-paid products.
Private sector provider training
Periodic (e.g. quarterly) monitoring of retail price and availability implemented by an independent enty in
order to guide management decisions on implementaon of the PSCM
Policy and/or regulatory changes at the country level (e.g. banning sales and importaon of artemisinin
monotherapies, granng waivers for import dues and taxes)

Fig. 2 Timeline of CPM supporting interventions implementation

AMFm were devolved to national level under the responsibility of the Global Fund Principal Recipient (PR) with
guidance from a national co-payment task force. Key
changes in the mechanism that occurred in the transition
from AMFm to CPM are detailed in Table 1.
With devolution of certain components of the CPM
to country level, there was more room for variation
between countries in subsidy levels, and greater flexibility to respond to local anti-malarial market conditions.
Table 2 outlines changes in subsidy levels that occurred
within each country post-pilot through 2015. Madagascar was the only AMFm country in this study to maintain the 95% subsidy for first-line buyers. Elsewhere, the
subsidy level was reduced to as low as 70% in Kenya and
Uganda.
The extent to which any of the successes identified
in the independent evaluation of the AMFm have been
maintained or improved upon with implementation of
the CPM is unreported in the literature to-date. The aim
of this paper is to analyse what happened to QAACT
market share, availability and price in the private forprofit sector during the period following the AMFm.
Specifically, we use ACTwatch outlet survey data to

examine to what extent the changes observed during the
2010–2011 evaluated period of the pilot were maintained
with implementation of the CPM through 2014/15 in
five countries, and where they were maintained, whether
there have been significant improvements in those
indicators.

Methods
ACTwatch was launched in 2008 by Population Services
International (PSI) in collaboration with the London
School of Hygiene and Tropical Medicine with support
from the Bill and Melinda Gates Foundation. The goal
of the project was to generate timely, relevant and high
quality evidence about anti-malarial markets for policy
makers, donors and implementing organisations. As of
2016, ACTwatch had gathered data from a total of 12
malaria endemic countries in sub-Saharan Africa and the
Greater Mekong Sub-region. This paper presents data
from outlet surveys in five sub-Saharan countries that
took part in the AMFm pilot. It excludes data from other
countries that were not part of the AMFm pilot. Detailed
ACTwatch project and methodological information have
been published elsewhere [13, 14].

Supplier management was handled centrally under the AMFm and the CPM

A maximum price approach was outsourced to a negotiating agent

The Global Fund determined first line buyer eligibility to participate and sent
Local Fund Agents to conduct spot checks to monitor compliance with the
terms and conditions of the agreement

The Global Fund AMFm Unit approved all orders, initially on demand, and then on One to four rounds for ordering per calendar year per country, and the PR had to
a monthly basis
review, validate and approve each round of co-payment allocations before the
Global Fund could notify manufacturers of orders approved for co-payment

The Global Fund commissioned an independent evaluation and price-tracking
surveys

Supplier management

Price negotiations

First-line buyer responsibilities

Order approvals

Monitoring and evaluation

PRs were responsible for tracking price and availability in the private sector

PRs assessed first-line buyers, determined eligibility, maintained and oversaw
agreements, and conducted spot checks for compliance with the terms and
conditions of the agreement

A competitive tender was managed by the Sourcing Department at the Global
Fund Importantly, this resulted in a supplier- and product-specific reduction in
prices of about 30%. This reduction has offset the falls in subsidy levels in some
countries

Since 2013, countries have set their own subsidy levels and these have evolved
over time

Set by the Global Fund Secretariat and applied across all pilots. The subsidy level
under the AMFm was targeted at 95%, but in practice it differed by formulation
and pack size

Subsidy level

The Country Coordinating Mechanism at country level provided oversight of
implementation by the PR of the grant

A sub-committee of the Global Fund Board provided oversight of the Secretariat

CPM

Oversight responsibilities

AMFm

Table 1 Key features of the AMFm and CPM. Source: Personal Communication, The Global Fund, 24/08/2016
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Table 2 Subsidy levels for the CPM. Source: Personal Communication, The Global Fund, 24/08/2016
Nigeria

Early to mid-2013: changed to 85% subsidy for all pack
sizes

Kenya

Early to mid-2013: changed to 70% subsidy for all pack
sizes

Tanzania

Early 2014: changed to 80% adult and 90% paediatric
subsidy levels
Early 2015: changed to 75% adult and 85% paediatric
subsidy levels.

Uganda

Early 2014: changed to 50% adult and 70% paediatric
subsidy levels
Mid- 2015: changed to 70% subsidy for all pack sizes

Madagascar

Maintained the 95% subsidy for all pack sizes

Design and sampling

ACTwatch outlet surveys are nationally-representative
cross-sectional quantitative surveys conducted among a
sample of outlets stocking anti-malarial medicines and
diagnostics. Surveys were repeated over time to inform,
monitor and evaluate policies and strategies designed
to improve access and use of malaria diagnostics and
first-line treatments. A detailed description of the ACTwatch outlet survey methods is available elsewhere [13].
Briefly, all categories of outlets with the potential to stock
anti-malarials in both the public and private sector were
included in the study. In the public sector, this included
government and non-government not-for-profit health
facilities (hospitals, centres, clinics and posts) and community health workers. Outlets sampled in the private
sector included private for-profit health facilities (hospitals, centres and clinics), pharmacies, drug stores (registered/regulated and unregistered/unregulated), general
retailers selling fast-moving consumer goods, and itinerant drug vendors (mobile vendors without a fixed service
delivery point).
Lists of all potentially eligible outlets were not routinely
available and therefore a cluster sampling approach with
an outlet census was used to identify outlets for inclusion. Clusters were administrative units ideally with
a typical size of 10,000–15,000 inhabitants, and were
selected using probability proportional to population size
sampling. Within each selected cluster all outlet types
with the potential to provide anti-malarials to consumers
were screened, with anti-malarial audits completed in all
outlets found to have one or more anti-malarials in stock
the day of the survey.
Boundaries for the outlet census were typically
extended to larger administrative units for the census of
public health facilities and pharmacies, in order to oversample these relatively uncommon but important outlet
types.
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Each study was stratified to deliver estimates for relevant research domains. All countries had urban and rural
stratification, with the exception of Nigeria in 2009, 2013
and 2015, for which six geopolitical zones were used as
research domains. Each study round was powered to
detect a minimum of a 20% point change in QAACT
availability among anti-malarial stocking outlets between
each round and within each domain at the 5% significance level with 80% power. The number of study clusters
was calculated for each research domain based on the
required number of anti-malarial stocking outlets and
assumptions about the number of anti-malarial stocking
outlets per cluster. Sample size requirements for followup surveys were calculated using information from previous survey rounds including anti-malarial and QAACT
availability, outlet density per cluster, and design effect.
Data collection periods varied by country and over
time but were typically during the peak malaria transmission season for each country and lasted between 6 weeks
and 2 months. Efforts were made to ensure surveys were
implemented over similar time points across the survey
rounds.
Training and fieldwork

Interviewer training consisted of standardized classroom
presentations and exercises as well as a field exercise.
Exams administered during training were used to select
data collectors, supervisors, and quality-controllers,
who received additional training. Data collection teams
were provided with a list of selected clusters and official
maps that illustrated administrative boundaries. In each
selected cluster, fieldworkers conducted a full enumeration of all outlets that had the potential to provide antimalarials. This included enumeration of outlets with a
physical location, as well as identification of community
health workers and itinerant drug vendors using local
informants. The primary provider/owner of each outlet was invited to participate in the study and screening
questions were administered to assess anti-malarial availability. Interviews were conducted in the local language
using questionnaires that were translated from English to
the local language and back to English to confirm translations. All surveys were paper-based with the exception of Madagascar 2015 and Uganda 2015, where data
were collected using Android phones and forms created
using DroidDB (©SYWARE, Inc., Cambridge, MA, USA).
Quality control measures implemented during data collection included questionnaire review by supervisors
and interview verification visits conducted by quality
controllers to between 10 and 20% of all outlets. Any discrepancies that were found were resolved. Double data
entry was conducted using Microsoft Access (Microsoft
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Corporation, Redmond, WA, USA) with built-in range
and consistency checks.
Information collected on anti‑malarials

The outlet survey questionnaire included an audit of all
available anti-malarial medicines. Providers were asked
to show the interviewer all anti-malarial medicines currently available. A product audit sheet captured information for each unique anti-malarial product in the outlet,
including formulation, brand name, active ingredients
and strengths, package size, manufacturer and country
of manufacture. Providers were asked to report the retail
price for each medicine as well as the amount distributed
to individual consumers (as opposed to wholesale purchasers) in the last week.
Data analysis

Data were analysed across survey rounds using Stata
(StataCorp College Station, TX) and R (©The R Foundation, Vienna, Austria). Standard indicators were constructed according to definitions applied across the
ACTwatch project and have been described in detail elsewhere [1, 14]. Briefly, anti-malarials identified during the
outlet drug audit were classified according to information
on drug formulation, active ingredients and strengths
as non-artemisinin therapies, artemisinin monotherapies and ACT. Non-artemisinin therapies were classified
as sulfadoxine pyrimethamine (SP) or other non-artemisinin therapies. Although no longer indicated for
malaria case management, SP is still purchased for case
management and recommended in all study countries for
intermittent preventive therapy of malaria during pregnancy (IPTp). Artemisinin monotherapies were further
classified as oral and non-oral, the latter including medicines recommended for the first-line treatment of severe
malaria. ACT were classified as QAACT or non-QAACT.
QAACT were ACT granted World Health Organization (WHO) prequalification, ACT in compliance with
the Global Fund Quality Assurance Policy, on the Global
Fund list of approved pharmaceutical products for procurement, or ACT granted regulatory approval by the
European Medicines Agency (EMA). Classification was
completed by matching product audit information (formulation, active ingredients, strengths, manufacturer,
country of manufacture and package size) to the most
recent lists of approved medicines available from the
WHO, Global Fund, and EMA for each survey round.
Anti-malarial market composition was defined as the
percentage breakdown of anti-malarial outlets by type,
with anti-malarial outlets defined as all those with antimalarials in stock on the day of the survey. QAACT
availability is presented out of those outlets that had
anti-malarials in stock. Significant differences in QAACT
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availability levels between years in each country were
estimated using logistic regression, with a binary dependent variable for availability of QAACT at the outlet level,
and a dummy independent variable for year.
To calculate market share, anti-malarial sales were
standardized to allow meaningful comparisons between
anti-malarials with different treatment courses and different formulations. The adult equivalent treatment dose
(AETD) was defined as the amount of active ingredient
required to treat an adult weighing 60 kg according to
WHO treatment guidelines [3]. Provider reports on the
amount of the drug sold or distributed during the week
preceding the survey were used to calculate volumes in
AETDs according to type of anti-malarial. Measures of
volume included all dosage forms to provide a complete
assessment of anti-malarial market share. The statistical
significance of differences in QAACT market share was
estimated using Stata’s ratio command, and the post-estimation ‘lincom’ (linear combination) command.
Median private sector price per AETD was calculated
for QAACT and for the most popular non-artemisinin
therapy in the most recent round, SP. The interquartile range (IQR) is presented as a measure of dispersion.
Price data were collected in local currencies and deflated
to 2009 US dollar prices using national consumer price
indices and published exchange rates for the period of
data collection. While all QAACT are by definition tablet
formulations, SP may be available in other formulations
including syrups and injections. Price measures included
tablet anti-malarials only, given differences in unit costs
for tablet and non-tablet formulations. Statistical significance for year on year differences in median price in
each country was estimated in R, using the Mann–Whitney–Wilcoxon test. Because this test provides a measure
of relative rank, rather than strictly testing for the difference between two medians, it is possible that significant
differences will be identified when there is no difference
between the medians themselves [15]. This therefore
would represent a difference in the price distribution
between 2 years, rather than directly a difference between
two medians.
Sampling weights were calculated as the inverse of the
probability of cluster selection. All point estimates were
weighted using survey settings and all standard errors
calculated taking account of the clustered and stratified
sampling strategy with the relevant suite of survey commands in each statistical package.

Results
A total of 139,738 outlets were screened to assess availability of anti-malarial medicines across the five countries and 18 survey rounds between 2009 and 2015.
An audit of all available anti-malarials was completed
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in 34,441 outlets. In total, 242,541 anti-malarial drugs
were audited. Table 3 shows a detailed breakdown of the
screening and audit results for each survey round.
The private sector constituted the majority of service
delivery points for malaria treatment provision in four
out of the five countries. Figure 3 shows that in terms
of absolute number of places where anti-malarial medicines were available, most were categorized as private
for-profit outlets. Only Madagascar had a majority of
outlets in the public/not-for-profit sector, where community health workers represented 51.7% of all outlets,
and a large majority, therefore, of all public sector outlets.
The private sector nevertheless represented a substantial proportion of the anti-malarial market in Madagascar. In the other four countries, drug stores tended to be
the most numerous outlet type among all those providing malaria treatment. In Nigeria and Tanzania, drug
stores accounted for more than half of all anti-malarial
service delivery points (76.0 and 70.2%, respectively).
Private for-profit health facilities and pharmacies tended
to be less numerous, although they accounted for a substantial proportion of all anti-malarial stocking outlets
in Kenya (21.4 and 11.8%, respectively). The extent to
which general retailers were part of the anti-malarial
market varied, from Uganda where general retailers were
not involved in anti-malarial distribution, to Kenya and

Madagascar where about one in five anti-malarial stocking outlets were general retail shops (19.8% in Kenya;
20.9% in Madagascar). In Kenya, this means that nearly
one in four (23.0%) private sector outlets providing antimalarials were general retailers, and in Madagascar, over
half (56.0%) of anti-malarial stocking private sector outlets were general retail outlets. Itinerant drug vendors
with anti-malarials in stock were uncommon across all
countries, although found in both Madagascar and Nigeria (2.5 and 1.1% of all outlets stocking anti-malarials,
respectively).
Private sector QAACT availability

Figure 4 summarizes the availability of QAACT among
anti-malarial stocking private sector outlets pre(2009/2010) and post-(2011) AMFm, and subsequently
during implementation of the CPM. QAACT availability
in the most recent survey round was greater than 70%
in Nigeria, Kenya, Tanzania and Uganda. The highest
level was found in Nigeria, where QAACT availability
exceeded 80% in 2015 (84.3%). Madagascar had a substantially lower level of QAACT availability, at 11.2% in
2015.
Significant increases were found in availability between
pairs of consecutive survey rounds in all countries for
at least one post-2011 time period. In Nigeria, QAACT

Table 3 Results of the outlet census and anti-malarial audit by country and survey year
Country

Year

Screened (N)

Outlets the met screen‑ Anti-malarial audit
ing criteria
complete (N)

Anti-malarials
audited (N)

QA ACT audited (N)

West & Central Africa
Nigeria

2009

5456

2210

2113

20,841

1192

2011

7938

1567

1486

13,391

2119

2013

5148

1828

1714

14,358

4799

2015

13,483

3624

3473

33,532

9581

East Africa
Kenya

Tanzania

Uganda

2010

13,897

2625

1888

8376

2052

2011

11,383

2112

1854

9544

3669
3234

2014

12,676

2477

2133

9899

2010

3120

710

624

5544

416

2011

3702

799

787

9701

2045

2014

4724

2160

2129

17,307

4905

2010

11,153

2590

2410

14,427

2893

2011

16,207

3285

3138

20,283

5495

2013

7932

3504

3307

19,777

7182

2015

9438

4780

4328

26,640

7380

Southern Africa
Madagascar

2010

6769

2642

2414

5579

1790

2011

10,046

2854

2360

7234

3233

2013

10,149

2021

1756

6101

3851

2015

13,481

1361

1040

3170

1501

ACTwatch Group et al. Malar J (2017) 16:173
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Nigeria 2015, N=3470

Kenya 2014, N=1501

Public health facility
Community health workers
Private not-for-profit facility
Private for-profit facility
Pharmacy
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Fig. 3 Anti-malarial market composition by country for the most recent survey round

availability rose by 21% points in the period 2011–2013
(p < 0.001) and then by a further 10% points through
2015 (p < 0.05). Kenya and Tanzania also experienced
statistically significant increases in availability of 10%
points (p < 0.05) and 16% points (p < 0.001) respectively
between 2011 and 2014. In Uganda, a significant increase
in availability was observed between 2011 and 2013, and
this level of availability (over 75%) was also maintained in
the most recent survey round (no significant difference).
In Madagascar, there was no significant rise in availability
during AMFm, however QAACT availability increased
by 19% points between 2011 and 2013 (p < 0.001), but
decreased significantly to near pre-AMFm levels in 2015
(p < 0.001).
Private sector anti‑malarial market share

Figure 5 summarizes QAACT anti-malarial market share
in the private sector pre- (2009/2010) and post- (2011)
AMFm, and subsequently during implementation of the
CPM. Market share is also shown for non-QAACT, nonartemisinin therapies and artemisinin monotherapies.
The share of private for-profit anti-malarial distribution
accounted for by QAACT varied across countries, but

was less than 50% in all countries. In the most recent survey round, it was highest in Kenya and Uganda (at 48.2
and 47.5%, respectively), followed by Tanzania (39.2%)
and Nigeria (35.0%). QAACT market share was lowest in
Madagascar (7.0%) in 2015.
QAACT market share in all five countries increased
during the AMFm period (p < 0.001). In both Tanzania and Uganda, QAACT market share increases were
maintained (no significant change compared with post2011 levels), while in Nigeria there were further statistically significant increases in QAACT market share
between survey rounds (p < 0.001 between 2011-2013
and 2013-2015). Kenya saw a statistically significant
decrease in QAACT market share between 2011 and
2014 (p < 0.001). However, ACT market share in Kenya
remained similar between 2011 and 2014 with nonQAACT appearing to have displaced QAACT during
this period. In Madagascar, initial post-AMFm gains in
QAACT market share (p < 0.05) had been eliminated
by the most recent survey round, with large, significant
declines (p < 0.001), returning to pre-AMFm levels.
Data within each type of private sector outlet show
that QAACT market share improvements in the case of
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Fig. 4 Availability of QAACT among private sector anti-malarial stocking outlets. Significant difference in QAACT availability between the round
indicated and the previous round: ns not significant, * p < 0.05, *** p < 0.001

Nigeria, Tanzania and Uganda, and declines in Kenya and
Madagascar were not necessarily uniform across all outlet types (Additional file 1).
Non-artemisinin therapies accounted for about onethird of all anti-malarials distributed in the private sector
during the most recent survey rounds in Kenya (30.2%)
and Uganda (32.0%), almost half in Nigeria (48.8%) and
over half in Tanzania (55.7%) and Madagascar (93.6%).
The most common type of non-artemisinin therapy distributed in each country’s private sector was SP.
Oral artemisinin monotherapy was found consistently
only in Nigeria’s private sector. Market share for oral
artemisinin monotherapy in Nigeria fell significantly
between 2011 and 2013 (p < 0.001), and did not increase
significantly between 2013 and 2015. Nevertheless, oral
artemisinin monotherapy accounted for 2.5% of market
share in the most recent survey round.
Private sector price

Four of the five countries experienced significant
decreases in median QAACT price during the AMFm
period (to 2011). Post-AMFm pilot, these prices were
maintained in Nigeria and Uganda to 2013 and then
underwent a decline in both countries between 2013
and 2015 (p < 0.001). In Tanzania, the median price of

QAACT remained the same between 2011 and 2014,
however the distribution of prices, as illustrated in the
upwards shift in IQR, resulted in a statistically significant
test results for price trend (p < 0.001). Price increased
significantly in Kenya between 2011 and 2014 (p < 0.001),
although remained consistently below pre-AMFm levels. The price of QAACT in Madagascar rose during the
AMFm period, and despite small but significant price
declines between 2011 and 2013 (p < 0.001), QAACT
price increased between 2013 and 2015 (p < 0.001)
(Fig. 6). This rise was likely due to large price increases
per AETD of artemether-lumefantrine (AL) in Madagascar in that period, as artesunate-amodiaquine (ASAQ)
price remained stable.
SP prices were consistently lower than those of
QAACT in both the AMFm and CPM periods, with the
exception of Kenya and Tanzania in 2011, where they
were equal. Price differences between SP and QAACT
have narrowed considerably since 2009/2010. In the most
recent survey round, QAACT and SP prices were most
similar in Tanzania (in 2014), when QAACT remained
1.3 times more expensive than SP. In all other countries,
QAACT were two to three times more expensive than SP
during the most recent survey round (Nigeria, 3.4; Kenya,
2.6; Uganda, 3.4; Madagascar, 2.8) (Additional file 2).
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Fig. 5 Private sector market share by anti-malarial type. Significant difference in QAACT market share between the round indicated and the previous round: ns not significant, * p < 0.05, ** p < 0.01, *** p < 0.001

Price data were disaggregated by package size for the
most common QAACT type in each country (ASAQ in
Madagascar, AL in the other four countries) (Figs. 7, 8,
9, 10). Post-AMFm falls in prices seen at aggregate level
in Uganda and Nigeria clearly occurred across all package sizes. Post-AMFm increases in price in Kenya and
Tanzania were observed for larger pack sizes, but not for
AL 6-tablet pack in both countries, and the AL 12-tablet
pack in Tanzania.

Discussion
This paper examined whether the successes of the
AMFm in improving availability, market share and price
of QAACT between 2010 and 2011 [9] were maintained
or improved upon with continuation of a private sector co-payment mechanism administered by the Global
Fund through 2014/15. The results are particularly significant given the importance of the private sector in
distributing anti-malarial drugs in these countries [1,
4]. While encouraging, findings also highlight a need for

further improvements in QAACT uptake in the private
sector.
The improvements in anti-malarial markets observed in
this study occurred in the context of an evolution in the
copayment mechanism, from highly centralized management under the controlled conditions of the time-limited
AMFm pilot to decentralization of management and oversight to the national level in the CPM period. Each country
set new subsidy levels, most often reducing the subsidy for
first-line buyers, with the exception of Madagascar where
the high subsidy level under AMFm was maintained.
Supporting interventions were largely not systematically
implemented across countries during the CPM period,
with the exception of reported mass communications
regarding the subsidy in Kenya. Implementation strength
of supporting interventions was not measured. The number of co-paid ACT delivered to the private sector peaked
after the period covered by the independent evaluation of
AMFm in each country, indicating that demand and successful resupply for first-line buyers continued under the
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Fig. 7 Package price for paediatric dose AL or ASAQ, in 2009 USD

decentralized CPM model. These findings demonstrate
operational effectiveness under sustained implementation
outside of a tightly controlled pilot.
Post‑AMFm anti‑malarial market improvements

In the post-AMFm period, there were statistically significant increases in private sector QAACT availability
in Kenya, Madagascar, Nigeria, Tanzania and Uganda,
but with a subsequent fall in the case of Madagascar.
Furthermore, the vast majority of private sector outlets

with anti-malarials in stock had QAACT in stock during each survey round in all countries except Madagascar. The majority of people seeking malaria treatment
in these countries do so in the private sector, and these
results indicate that throughout the CPM period, they
were likely to find QAACT in these private outlets,
whereas before AMFm implementation this was not the
case. Furthermore, post-AMFm QAACT market share in
the private sector was maintained or further increased in
Nigeria, Tanzania and Uganda.
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Fig. 10 Package price for one adult dose of AL or ASAQ, in 2009 USD

Persistent challenges to increased QAACT uptake

Despite these broadly positive results for availability and
market share, there was evidence of a persistent gap in
the uptake of QAACT after 4–5 years of a private sector
copayment mechanism (2010–2014/15). While it should
be recognised that implementation varied over time and
across countries, and that funding and subsidy levels fell

after the initial pilot period, it was notable that QAACT
market share in the private sector remained at less than
50% in each country. Non-artemisinin therapies, particularly SP, accounted for one-third to one-half of all
anti-malarials distributed in Kenya, Nigeria, Tanzania
and Uganda, and over 90% of anti-malarials distributed in Madagascar. Non-artemisinin therapies should
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continue to account for a small portion of anti-malarial
market share in all of these countries because SP is recommended for IPTp [3]. However, persistent substantial
SP market share is cause for concern. Continued uses of
SP likely include management of fever/malaria in people
of all ages given the widespread availability of products
with packaging and patient instructions for uncomplicated malaria.
The continuing sub-optimal QAACT market share,
despite high availability, highlights the need for expansion of supporting interventions to promote QAACT
uptake. Persistent distribution of non-artemisinin therapies despite availability of ACT has been documented
in a number of countries within public and private sectors and well before the AMFm pilot [16, 17]. Provider
behaviour is one contributing factor to low ACT demand
and use, and may reflect low levels of provider awareness
about recommended first-line treatments and/or beliefs
and preferences for non-first-line medicines [18–20].
Within the context of the AMFm, there is some evidence
to suggest that communications campaigns implemented
as part of the AMFm pilot may have been effective in
increasing private provider knowledge regarding the
first-line treatment [21]. However, awareness of official
guidance is unlikely sufficient to drive ACT uptake alone
and strategies are needed to influence not only provider
knowledge but also provider preferences [22]. There is
some evidence to suggest that trainings for providers
in the informal private sector may have benefits [23].
Trainings targeting private providers were reportedly
implemented as part of the CPM in Kenya and Nigeria,
although evidence about implementation strength and
effectiveness of these trainings is not available. There is
need for additional evidence about private provider preferences and practices to inform appropriate strategies to
facilitate changes in stocking and dispensing behaviours
in the context of mechanisms such as the CPM.
Low QAACT uptake is also influenced by consumer
demand [20]. There is a gap in the contemporary evidence base for information on factors influencing consumer treatment-seeking behaviour. While a number
of studies concerning patient treatment-seeking behaviour were conducted and summarized in key reviews
in the 1990s and early 2000s [24, 25], there is need for
updated evidence, particularly in the context of largescale investments and strategies to improve malaria case
management in public and private sectors. The primary
supporting intervention targeting consumers under the
AMFm and CPM was mass media communications campaigns with a focus on promoting ACT with the green
leaf logo and in some instances, the recommended retail
price. These were implemented to varying degrees across
countries, however evidence on implementation strength
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and effectiveness vis-à-vis QAACT uptake is not available. Mass media communications campaigns have been
shown to play an important role in a range of health
interventions, particularly when part of a wider set of
activities [26]. Although behaviour change communication has been a critical component of malaria strategies,
most programs have not been rigorously evaluated. Evidence is limited on effectiveness of various approaches
and materials as well as on the overall effectiveness of
communications for behaviour change in this context
[27].
The relatively high cost of QAACT, despite reductions
in price with AMFm and CPM interventions, may also
be limiting QAACT update. SP remains less expensive
than QAACT in all study countries, and QAACT were
two to three times more expensive than SP during the
most recent survey round in Kenya, Madagascar, Nigeria
and Uganda. Reducing ACT retail price increases ACT
use [6, 11], but results of this study suggest that retail
prices achieved through the CPM model may not be low
enough to achieve optimal uptake.
In addition to supporting interventions targeting provider and consumer behaviour, the policy and regulatory
environment may influence the success of copayment
mechanisms [24]. Strengthened policies and regulations
may be needed to curtail the availability and distribution
of artemisinin monotherapies for malaria case management [28].
Finally, the requirements for such supporting interventions are evolving in line with the goals of malaria case
management in endemic country settings. WHO and
national programme guidelines now place emphasis on
confirmation of all suspected cases [29], meaning that
there is need to re-evaluate the primary threats and specific barriers to case management in the private sector,
and to develop locally tailored and global market-based
approaches that will be cost-effective in ensuring not only
use of appropriate and effective malaria treatments but
also appropriate diagnosis.
Market deteriorations

In contrast to the generally positive trends in key indicators in Nigeria, Tanzania and Uganda, results were mixed
in Kenya and highly unfavourable in Madagascar. While
QAACT availability in Kenya increased post-AMFm to
just over 70%, market share significantly declined to less
than 50% coinciding with a drop in subsidy level from
95% to 70%. At the same time, market share for nonQAACT increased such that one in five anti-malarials
distributed in Kenya in 2014 were non-QAACT, indicating that QAACT were to some extent displaced by nonQAACT between 2011 and 2014 [30]. This is concerning
given potential threats to patient health and malaria
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parasite clearance associated with using sub-standard
medicines [31–35]. What appears to be a rising demand
for and use of non-QAACT is particularly surprising
given that Kenya reported implementing mass communications during the AMFm and continuing throughout
CPM implementation. However, the reach and consistency of these communications has not been formally
assessed and effectiveness has not been established. It is
also interesting to consider if a more gradual reduction in
subsidy level over time might have preserved some of the
QAACT market share in Kenya despite the retail price
increase that would be expected following a reduction
in subsidy level. Evidence is needed to inform additional
strategies to generate and sustain demand for qualityassured products.
In Madagascar, the AMFm yielded no significant
improvements in private sector QAACT availability and
significant but minimal improvements in private sector
QAACT market share. Post-AMFm, QAACT market
share and price increased to moderate levels between
2011 and 2013, but then declined to pre-AMFm levels by
2015. The CPM in Madagascar was halted between 2014
and late 2015 following an investigation by the Global
Fund’s Office of the Inspector General, resulting in very
few co-paid ACT being delivered before the end of 2015,
with only one round of co-payments held at the end of
that year. The country’s 2009–2014 political crisis also
had limiting effects on the extent of external donors’ support for health programmes in the public sector, with
health commodity stock-outs and overall weak national
health infrastructure and commodity management systems continuing to pose challenges [36]. Furthermore,
an interruption to major Global Fund-funded activities
during this period resulted in widespread ACT stockouts nationally. Further to these supply chain and health
system problems, the supporting interventions relating
to the CPM had not started as of the final survey round
reported here (in 2015) (Personal Communication, The
Global Fund). The relatively poor results in Madagascar
can therefore perhaps be better understood as a reflection of poor implementation, rather than the failure of a
well-implemented programme.

Limitations
This study has several limitations. First, the complex
nature of the CPM, operating at national level in several
countries with heterogeneous anti-malarial distribution
chains and markets has meant that there were no good
controls at sub-national or national level to use as comparators in this analysis. The degree to which we could
make any kind of causal claims as to the effect of the
CPM is therefore limited. Nevertheless, seen in the context of the results of the AMFm independent evaluation,
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the evidence presented here from the post-pilot period
is suggestive of continued effects of ‘factory gate’ subsidies on the QAACT markets in the countries where the
mechanism was active. Furthermore, a systematic review
of the literature examining the effects of subsidies on key
ACT indicators suggested that in smaller-scale RCTs,
there was strong causal evidence that these subsidies
could be successful in reducing ACT prices and increasing their availability and market share in a range of settings [37]; this reinforces the findings presented here.
A further limitation is our reliance on self-report survey
data. In each country’s outlet surveys, while anti-malarial
audits were carried out by researchers, still depended on
prices and sales volumes reported by the outlet supervisor. These responses were open to positive response bias.
Differential levels of response bias for SP versus QAACT
would not, however, necessarily be expected. It is possible though that there may be differential levels of response
bias between survey rounds, as the emphasis placed on
recommended retail price (RRPs) may have varied over
time. As our focus has been on price difference between
these two anti-malarials, rather than their absolute levels, the effect of this potential bias should be limited here.
Using price per AETD permits price comparisons over
time, and between types of anti-malarial drugs, but we
acknowledge that this measure is less useful in understanding what consumers typically pay for treatment, as
this varies according to various factors such as pack size.

Conclusions
Improving the case management of malaria in the private
sector is critical to improving coverage of appropriate
malaria case management in many endemic countries.
The results presented in this paper demonstrate that
a private sector co-payment mechanism for QAACT,
implemented at national scale for 5 years was associated
with positive and sustained improvements in QAACT
availability, price and market share in three out of five
countries. These included the large West African country of Nigeria, with one of the highest malaria burdens in
the world, as well as the East African countries of Uganda
and Tanzania. Furthermore, substantial improvements
in QAACT availability, price and market share observed
during the AMFm period continued in these three countries as they transitioned to the CPM, characterized by
decentralized management and national oversight of
implementation. Mixed results were observed in Kenya,
where post-AMFm QAACT market share was not maintained and QAACT appeared to have been displaced in
part by non-QAACT following a reduction in the subsidy level while the quantity of co-paid QAACT delivered remained nearly constant. It is worth noting though
that the QAACT market share remained well above
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pre-AMFm levels. In Madagascar, a number of contextual
factors appear to have contributed to a lack of sustained
market improvements under both the AMFm and CPM,
including halted implementation of the programme.
Results from this study suggest that a co-payment mechanism for QAACT targeting the private sector can be an
effective and feasible strategy to improve availability and
use of appropriate malaria treatment in malaria-endemic
countries that have a substantial private sector market. However, results also demonstrate that this subsidy
mechanism was not sufficient alone to drive QAACT
uptake to 100%. Supporting interventions to address
availability and distribution of non-artemisinin therapies
and to create demand for QAACT among providers and
consumers may be needed to realize the full potential of
this type of subsidy mechanism. Furthermore, there is
need for comprehensive market assessments in malaria
endemic countries to identify contemporary market barriers to high coverage with not only appropriate malaria
treatment but also confirmatory testing of all suspected
cases.
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